Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Liabilities and Shareholders Equity: 2020-2024

Historic Liabilities and Shareholders Equity for Caribou Biosciences (CRBU) over the last 5 years, with Dec 2024 value amounting to $313.3 million.

  • Caribou Biosciences' Liabilities and Shareholders Equity fell 43.37% to $195.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 35.56%. This contributed to the annual value of $313.3 million for FY2024, which is 27.51% down from last year.
  • According to the latest figures from FY2024, Caribou Biosciences' Liabilities and Shareholders Equity is $313.3 million, which was down 27.51% from $432.2 million recorded in FY2023.
  • Over the past 5 years, Caribou Biosciences' Liabilities and Shareholders Equity peaked at $442.4 million during FY2021, and registered a low of $36.0 million during FY2020.
  • Its 3-year average for Liabilities and Shareholders Equity is $373.1 million, with a median of $373.8 million in 2022.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 1,127.20% in 2021, then decreased by 27.51% in 2024.
  • Yearly analysis of 5 years shows Caribou Biosciences' Liabilities and Shareholders Equity stood at $36.0 million in 2020, then soared by 1,127.20% to $442.4 million in 2021, then fell by 15.51% to $373.8 million in 2022, then climbed by 15.64% to $432.2 million in 2023, then declined by 27.51% to $313.3 million in 2024.